Skip to main content

Russia Covid-19 vaccine: Over 250 people in Moscow get inoculated

The Russian government on Monday said that over 250 Moscow residents have got the dose of its first Covid-19 vaccine, Sputnik V, over the past five days, according to a report.

The vast majority of them are in good health, the anti-coronavirus crisis centre told reporters today.

"Over the past five days of clinical trials of the vaccine against the coronavirus infection over 250 Moscow residents got inoculated at the seven centres that opened first. Doctors closely monitor the health condition of the vaccinated. The absolute majority is in excellent health - 75% of the participants today do not observe any symptoms or ailments," the crisis centre said, according to the Russian news agency.

On Friday, Russian Health Minister Mikhail Murashko told reporters that the first batch of Russia's Covid-19 vaccine was likely to be delivered to all regions of the country by 14 September, according to TASS.

"The first batches of the vaccine for testing the supply chain have already been shipped, we are now checking the delivery system so that the staff gets to know it. The first small batches have already been shipped to all regions, the Leningrad region will also receive [the vaccine] among the first ones. In fact, the first samples of the vaccine will be delivered by Monday," Murashko had said.

The development comes after a week of Russia releasing the first batch of the Sputnik V vaccine into civil circulation, the Russian Health Ministry informed.

Sputnik V Covid vaccine, which is developed by Gamaleya Research Institute of Epidemiology and Microbiology under the Russian Health Ministry, may be granted permission to release a batch of its vaccine for civilian use, the institute’s deputy director for research, associate member of the Russian Academy of Sciences, Denis Logunov said earlier, according to a report.


Russia Covid-19 vaccine: Over 250 people in Moscow get inoculated, says report


Russian Sputnik V covid vaccine is undergoing Phase 3 trials

Russia Covid-19 vaccine: Over 250 people in Moscow get inoculated, says report

The vast majority of them are in good health, the anti-coronavirus crisis centre says

The development comes after a week of Russia releasing the first batch of the Sputnik V vaccine into civil circulation


Topics

Coronavirus Vaccine TrackerCovid-19Sputnik VRussia

The Russian government on Monday said that over 250 Moscow residents have got the dose of its first Covid-19 vaccine, Sputnik V, over the past five days, according to a report.

The vast majority of them are in good health, the anti-coronavirus crisis centre told reporters today.

"Over the past five days of clinical trials of the vaccine against the coronavirus infection over 250 Moscow residents got inoculated at the seven centres that opened first. Doctors closely monitor the health condition of the vaccinated. The absolute majority is in excellent health - 75% of the participants today do not observe any symptoms or ailments," the crisis centre said, according to the Russian news agency.

On Friday, Russian Health Minister Mikhail Murashko told reporters that the first batch of Russia's Covid-19 vaccine was likely to be delivered to all regions of the country by 14 September, according to TASS.

"The first batches of the vaccine for testing the supply chain have already been shipped, we are now checking the delivery system so that the staff gets to know it. The first small batches have already been shipped to all regions, the Leningrad region will also receive [the vaccine] among the first ones. In fact, the first samples of the vaccine will be delivered by Monday," Murashko had said.

The development comes after a week of Russia releasing the first batch of the Sputnik V vaccine into civil circulation, the Russian Health Ministry informed.

Sputnik V Covid vaccine, which is developed by Gamaleya Research Institute of Epidemiology and Microbiology under the Russian Health Ministry, may be granted permission to release a batch of its vaccine for civilian use, the institute’s deputy director for research, associate member of the Russian Academy of Sciences, Denis Logunov said earlier, according to a report.

On August 11, Russia became the first country to license a Covid-19 vaccine, calling it "Sputnik V" in homage to the world's first satellite, launched by the Soviet Union. But western experts have warned against its use until all internationally approved testing and regulatory steps have been taken. The vaccine is undergoing Phase 3 trials.

The vaccine produced an antibody response in all participants in early-stage trials, according to results published by The Lancet medical journal earlier that were hailed by Moscow as an answer to its critics.

The results of the two trials, conducted in June-July this year and involving 76 participants, showed 100% of participants developing antibodies to the new coronavirus and no serious side effects, The Lancet said.

However, a group of international scientists questioned results from the Lancet medical journal, saying some of the findings appeared improbable, reported Bloomberg.

The researchers flagged concerns over seemingly identical levels of antibodies in a number of study participants who were inoculated with the experimental vaccine. This and other patterns in the data present “several different points of concern," according to an open letter written by Temple University professor Enrico Bucci and signed by more than a dozen other scientists.


Comments

Popular posts from this blog

Iran, Russia Discussing Joint Production Of COVID-19 Vaccine

Iran and Russia's sovereign wealth fund RDIF are discussing the joint production of a vaccine against COVID-19, Russian news agencies cited the Iranian ambassador to Moscow as saying on Friday. "We are holding talks, I spoke with the head of RDIF Kirill Dmitriev, our officials have held several rounds of consultations and we announced that we will co-operate," Ambassador to Moscow Kazem Jalali was cited as saying. Thus far, Russia has struck a manufacturing partnership deal with India, which is due to produce 300 million doses of the 'Sputnik-V' vaccine domestically. It is also discussing such partnerships with several other countries, including Brazil.

Increased risks of drop out for women and girls : CoronaVirus Updates

The total number of children not returning to their education after the school closures is likely to be significant. The pandemic also risks jeopardizing some of the gains made since 2001 in re-building women and girls’ education following the Taliban regime.  The COVID-19 pandemic is creating additional barriers due to risks—and students’ and parents’ anxiety about risks—associated with children returning to classrooms that are cramped, with no capacity for distancing, often cold, damp and poorly ventilated during the country’s severe winters, and have no or poor hygiene and clean water facilities. The COVID-19 pandemic is likely to drive many women and girls out of education permanently. School closures due to COVID-19, resulting increases in caregiving responsibilities for women and girls, and increases in poverty and unemployment will all make it harder for women and girls to study.  These factors combine in harmful ways with pre-existing discriminatory gender norms, o...

Russia's Covid-19 vaccine Sputnik V available to public now: State media

First batches of Russia's Covid vaccine Sputnik V have entered "civil circulation" in capital Moscow, state media reported on Thursday. While details on the process were not immediately available, Russia has repeatedly stressed on producing the vaccine at the earliest, a belief met with international scepticism. Earlier this month, the Russian health ministry had said that batches of the Covid-19 vaccine were being produced for public distribution and would be supplied to different regions soon. "The first batch of the vaccine for preventing the novel coronavirus infection, Gam-COVID-Vac (Sputnik V) developed by the Gamaleya Research Institute of Epidemiology and Microbiology of the Russian Health Ministry passed the required quality tests in the laboratories of Roszdravnadzor (the Federal Service for Surveillance in Healthcare) and was produced for civilian circulation. In the near future the supplies of the first batches of the vaccine to the regions are expected...